Please join the CIBRN Leaders for an in-depth, cross-discipline discussion of CIBRN 2017 Question #1, Question #2 & Question #3 surrounding the implications of the evolving biosimilar landscape on clinical practice and patient health in Canada.
This webinar is intended for the ALL CIBRN members and is scheduled for Thursday, June 8th, 9:00-10:00 pm EST. Webinar connection details will follow by email.
Prior to the webinar, you are invited to visit the CIBRN community on Sosido to review the questions & responses and to reply with your personal clinical perspectives:
- Question #1: Does the availability of biosimilars impact upon your treatment algorithm for prescribing biologics in IBD?
- Question #2: What is your opinion on ‘non-medical switches’ in light of NOR-SWITCH and other evidence on biosimilars?
- Question #3: What measures can prescribers take to either prevent interchangeability or at least ensure that prescribers and patients are informed?
The webinar will be recorded and archived for future viewing by the CIBRN community.
If you have any comments or questions, please contact me at your convenience.
If you have never attended an Adobe Connect meeting before:
Test your connection: https://studio7communications.adobeconnect.com/common/help/en/support/meeting_test.htm
Get a quick overview: http://www.adobe.com/products/adobeconnect.html